Provided by Tiger Trade Technology Pte. Ltd.

Nektar Therapeutics

46.99
-13.5550-22.39%
Post-market: 47.000.0100+0.02%19:59 EDT
Volume:6.27M
Turnover:308.15M
Market Cap:1.60B
PE:-7.26
High:56.69
Open:55.41
Low:46.29
Close:60.55
52wk High:109.00
52wk Low:33.40
Shares:34.14M
Float Shares:28.53M
Volume Ratio:3.19
T/O Rate:21.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.4680
EPS(LYR):-9.7254
ROE:-35.75%
ROA:-12.54%
PB:1.78
PE(LYR):-4.83

Loading ...

Nektar Therapeutics : Wedbush Cuts Target Price to $80 From $95

THOMSON REUTERS
·
May 11

Nektar Therapeutics Charts Aggressive Path With REZPEG

TIPRANKS
·
May 09

Nektar Therapeutics Establishes New Equity Distribution Agreement

TIPRANKS
·
May 09

Nektar Therapeutics Names Rubinstein New Interim CFO

Dow Jones
·
May 09

BRIEF-Nektar Therapeutics May Offer And Sell Common Stock Up To $150 Million - SEC Filing

Reuters
·
May 09

Nektar Therapeutics - to Offer up to $150 Mln in Common Stock via Equity Distribution Agreement - SEC Filing

THOMSON REUTERS
·
May 09

Nektar Therapeutics - Sandra Gardiner to Retire as Interim CFO Effective May 15, 2026 - SEC Filing

THOMSON REUTERS
·
May 09

Nektar enters equity distribution deal for up to $150 million at-the-market offering

Reuters
·
May 09

Nektar Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
May 08

Nektar price target raised to $192 from $105 at Piper Sandler

TIPRANKS
·
May 08

Nektar Therapeutics: Strong Cash Position and Late‑Stage Autoimmune Pipeline Underpin Attractive Risk‑Reward and Outperform Rating

TIPRANKS
·
May 08

Nektar reports Q1 adjusted EPS ($1.82), consensus ($1.48)

TIPRANKS
·
May 08

Nektar Therapeutics Q1 net loss narrows on lower G&A costs

Reuters
·
May 08

Nektar Therapeutics Q1 EPS $(1.82) Misses $(1.62) Estimate, Sales $10.860M Beat $10.636M Estimate

Benzinga Earnings
·
May 08

BRIEF-Nektar Therapeutics Q1 EPS USD -1.82

Reuters
·
May 08

Nektar Therapeutics Reports First Quarter 2026 Financial Results

THOMSON REUTERS
·
May 08

A Look At Nektar Therapeutics (NKTR) Valuation After New REZOLVE AA Data Funding And Phase 3 Plans

Simply Wall St.
·
May 03

Nektar Therapeutics grants inducement equity awards to new hires under 2025 plan

Reuters
·
May 02

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 02

Earning Preview: Nektar Therapeutics this quarter’s revenue is expected to decrease by 30.74%, and institutional views are bullish

Earnings Agent
·
May 01